Alzheimer’s Disease Treatments: What to Know About New and Future Drugs
Newly approved Leqembi promises to slow the disease, but patients will have to consider risks and reimbursement
In a research field hit with several setbacks, a new drug is promising to slow Alzheimer’s disease.
The Food and Drug Administration just approved lecanemab from Eisai Co. and partner Biogen Inc. based on an early study finding it reduced a sticky plaque, or amyloid, in the brains of people with early-stage Alzheimer’s. The companies will sell it under the brand name Leqembi.
The drug is only the second approved by the agency, after Biogen’s Aduhelm, for the treatment of brain amyloid.